YUBO INTERNATIONAL BIOTECH LIMITED

(YBGJ)
Delayed OTC Markets  -  05/20 11:59:28 am EDT
0.0702 USD   -49.86%
05/16YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/16Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/15YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)

11/15/2021 | 04:53pm EDT

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements (unaudited) and the related notes and other financial information included elsewhere in this quarterly report on Form 10-Q and our consolidated financial statements (unaudited) included in our current report on Form 8-K field on January 14, 2021. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. You should review the subsection titled "Cautionary Note Regarding Forward-Looking Statements" below for a discussion of forward-looking statements and the section titled "Risk Factors" included in our current report on Form 8-K field on January 14, 2021 for a discussion of factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis and elsewhere in this quarterly report on Form 10-Q.

Cautionary Note Regarding Forward-Looking Statements

Some of the statements contained in this quarterly report on Form 10-Q discuss our plans and strategies for our business or state other forward-looking statements, as this term is defined in the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical facts may be deemed to be forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "plan," "intend," "should," "seek," "will," and similar expressions are intended to identify these forward-looking statements but are not the exclusive means of identifying them. These forward-looking statements reflect the current views of our management. However, various risks, uncertainties and contingencies could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, these statements. See our current report on Form 8-K filed on January 14, 2021 for a discussion of certain known risks.



Business Overview


We are a technology company focused on the research and development and application of endometrial stem cells. We are committed to building the first public endometrial stem cell repository in the world. We offer our products and services under the brand "VIVCELL". Our product offerings include healthcare products for respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. We also offer stem cell related services including cell testing and health management consulting services.

We are a U.S. holding company primarily operating in China through our wholly owned subsidiary, Platinum International Biotech Co., Ltd., a company organized under the laws of the Cayman Islands ("Platinum"), which in turn operates in China through its wholly-owned subsidiaries and contractual arrangements with a variable interest entity (the "VIE"), Yubo International Biotech (Beijing) Limited, a company organized under the laws of the People's Republic of China ("Yubo") that conducts our daily operations.

Key factors affecting our results of operations include revenues, cost of revenues, operating expenses and income and taxation.



History


We were incorporated as a New York corporation on February 22, 1991 and commenced operations on February 10, 1992. Prior to March 2003, our business had been focused on pre-revenue development and commercialization of disposable medical devices designed to enhance the effectiveness of magnetic resonance imaging in detection and diagnosis of heart disease. Due to the unavailability of funding, beginning in the Fall of 2002 we essentially ceased all of our operations including product development and commercialization activities. Our efforts to realize value for our prior business and MRI technology have been unsuccessful. As a result, we view our most viable option to be merging with an unrelated operating company that could benefit from our status as a reporting company in a so-called "reverse merger" transaction. In November 2006, our then shareholders approved a 1 for 100 reverse stock split of our common stock. On March 1, 2007, such reverse stock split became effective. Fractional shares were rounded up to the next full share.




          4

  Table of Contents




Change of Control


On September 23, 2020, Activist Investing LLC (the "Seller"), the owner of 116,697,438 common shares (the "Shares") upon conversion of $1,472,000 of promissory notes and accrued interest acquired by the Seller after the Seller purchased control of our Company in July 2020, agreed to sell the Shares to Lina Liu (the "Purchaser), a resident of China, for $255,000, pursuant to an Amended and Restated Stock Purchase Agreement (the "Stock Purchase Agreement"). The first agreement between the Seller and the Purchase was superseded because it had the incorrect name of the Seller. The Seller is owned 100% by David Lazar. The Shares represent approximately 99.0% of the 117,875,323 Class A common shares outstanding at November 30, 2020.

The sale of the Shares to Ms. Liu was completed on October 2, 2020. Ms. Liu, as our 99.0% majority shareholder, then appointed Jun Wang, Yang Wang and Zhihui Bai as members of our board of director (the "Board") and Ms. Liu as a director and CFO, Treasurer and Secretary (together, the "Designees"). As a result, there was a change of control of our Company; and the change of management was completed on or about October 12, 2020 (the "New Management Date"), ten (10) days after our Information Statement pursuant to SEC Rule 14f-1 was filed with the SEC and mailed to our stockholders. There is no family relationship or other relationship between the Seller and the Purchaser.

In connection with the sale under the Stock Purchase Agreement, Mr. Lazar resigned as an officer and director, and John B. Lowy and Dovid Kotkes have resigned as directors, and have appointed the Designees as our directors, on the New Management Date. As a result thereof, the Designees became our directors, on or about October 12, 2020.



Name Change


After obtaining the approval of the Board and the majority stockholder, we amended our Article of Incorporations by filing of a Certificate of Amendment changing the name of the Company to "Yubo International Biotech Limited" under stock symbol "YBGJ". The name change became effective December 4, 2020, pursuant to the Certificate of Amendment, upon completion of processing by the Financial Industry Regulatory Authority and in accordance with the SEC rules and regulations.

Reverse Merger with Platinum International Biotech Co., Ltd.

On January 14, 2021 (the "Closing Date"), we entered into a voluntary share exchange transaction with Platinum International Biotech Co., Ltd., a company organized under the laws of the Cayman Islands ("Platinum"), pursuant to that certain Agreement and Plan of Share Exchange, dated January 14, 2021 (the "Exchange Agreement"), by and among us, Platinum, Yubo International Biotech (Beijing) Limited, a company organized under the laws of the People's Republic of China ("Yubo"), and certain selling stockholders named therein.

In accordance with the terms of the Exchange Agreement, on the Closing Date, we issued a total of 117,000,000 shares of our Class A common stock to the then stockholders of Platinum (the "Selling Stockholders"), in exchange for 100% of the issued and outstanding capital stock of Platinum (the "Exchange Transaction"). As a result of the Exchange Transaction, the Selling Stockholders acquired more than 99% of our issued and outstanding capital stock, Platinum became our wholly-owned subsidiary, and we acquired the business and operations of Platinum and Yubo.

Platinum was incorporated on April 7, 2020 under the laws of the Cayman Islands as a holding company. Commencing April 2020, its consolidated variable interest entity Yubo is a leading supplier of innovative products that process, store and administer therapeutic doses of endometrial stem cells for treatment of disease and injuries in the PRC.

Immediately prior to the Exchange Transaction, we had 117,875,323 shares of Class A common stock and 4,447 shares of Class B common stock issued and outstanding. Immediately after the Exchange Transaction and the surrender and cancellation of 116,697,438 shares of Class A common stock previously held by Lina Liu, and as of the date hereof, our authorized capital stock consists of 120,000,000 shares of common stock, par value $.001 per share, of which 118,177,885 Class A common plus 4,447 Class B common) are issued and outstanding, and 5,000,000 shares of Preferred Stock, $.001 par value, none of which shares are issued or outstanding. Each share of Class A common stock is entitled to one vote with respect to all matters to be acted on by the stockholders; and each share of Class B common stock is entitled to five votes per share, and is convertible into one share of Class A common stock.




          5

  Table of Contents




COVID-19


On March 11, 2020, the World Health Organization declared the COVID-19 outbreak to be a global pandemic. In addition to the devastating effects on human life, the pandemic is having a negative ripple effect on the global economy, leading to disruptions and volatility in the global financial markets. Most U.S. states and many countries have issued policies intended to stop or slow the further spread of the disease.

COVID-19 and the U.S's response to the pandemic are significantly affecting the economy. There are no comparable events that provide guidance as to the effect the COVID-19 pandemic may have, and, as a result, the ultimate effect of the pandemic is highly uncertain and subject to change. We do not yet know the full extent of the effects on the economy, the markets we serve, our business, or our operations.

Critical Accounting Principles

This section discusses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. We consider certain accounting policies related to fair value measurements and earnings per share to be critical accounting policies that require the use of significant judgments and estimates relating to matters that are inherently uncertain and may result in materially different results under different assumptions and conditions. See Note 2 - Summary of Significant Accounting Policies.

As of September 30, 2021, the impact of COVID-19 on our business continued to unfold. As a result, many of our estimates and assumptions carry a higher degree of variability and volatility. As events continue to evolve and additional information becomes available, our estimates may change in future periods.

Recently Issued and Adopted Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update ("ASU") 201409, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This guidance was originally effective for interim and annual periods beginning after December 15, 2016 and allowed for adoption using a full retrospective method, or a modified retrospective method. The Company has adopted ASC 606.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02) "Leases (Topic 842)". ASU 2016-02 requires a lessee to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. ASU 2016-02 is effective for interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted.

Results of Operations for the Three Months Ended September 30, 2021 Compared to the Three Months Ended September 30, 2020 and for the Nine Months Ended September 30, 2021 Compared to the Nine Months Ended September 30, 2020




          6

  Table of Contents



Sales, Cost of Goods Sold and Gross Profit

We generated sales of $98,303 for the three months ended September 30, 2021, as compared to $194,459 for the three months ended September 30, 2020. Such decrease was primarily due to decrease in sale of oral liquid health products. Our cost of goods sold was $25,106 for the three months ended September 30, 2021, as compared to $62,990 for the three months ended September 30, 2020. Such decrease was primarily due to sale of oral liquid health products. As a result, our gross profit decreased from $131,469 for the three months ended September 30, 2020 to $73,197 for the three months ended September 30, 2021.

We generated sales of $913,103 for the nine months ended September 30, 2021, as compared to $471,148 for the nine months ended September 30, 2020. Such increase was primarily due to sale of oral liquid health products. Our cost of goods sold was $310,312 for the nine months ended September 30, 2021, as compared to $39,724 for the nine months ended September 30, 2020. Such increase was primarily due to sale of oral liquid health products. As a result, our gross profit increased from $431,424 for the nine months ended September 30, 2020 to $601,791 for the nine months ended September 30, 2021.



Operating Expenses


Our operating expenses were $419,211 for the three months ended September 30, 2021, as compared to $435,934 for the three months ended September 30, 2020. The decrease in operating expenses was primarily due to decreases in operating expenses partially offset by increases in employee compensation and occupancy.

Our operating expenses were $1,756,460 for the nine months ended September 30, 2021, as compared to $861,568 for the nine months ended September 30, 2020. The increase in operating expenses was primarily due to increases in employee compensation, occupancy, and other operating expenses.



Loss from Operations


Our loss from operations was $346,014 for the three months ended September 30, 2021, as compared to $304,465 for the three months ended September 30, 2020. The increase in loss from operations was due to decrease in gross profit $58,272.

Our loss from operations was $1,154,669 for the nine months ended September 30, 2021, as compared to $430,144 for the nine months ended September 30, 2020. The increase in loss from operations was due to increase in gross profit $170,367 offset by increase in operating expense of $894,892.



Other Income (Expense)


Our other expense (income) was $9,430 for the three months ended September 30, 2021, as compared to $(247) for the three months ended September 30, 2020. The increase in other expense was primarily due to write off of an intangible asset.

Our other expense (income) was $9,402 for the nine months ended September 30, 2021, as compared to $(157) for the nine months ended September 30, 2020. The increase in other income was primarily due to write off of an intangible asset.




Net Loss


Our net loss was $336,584 for the three months ended September 30, 2021, as compared to $304,712 for the three months ended September 30, 2020. The increase in net loss was primarily due to decrease in gross profit $58,272.

Our net loss was $1,145,267 for the nine months ended September 30, 2021, as compared to $430,301 for the nine months ended September 30, 2020. The increase in net loss was primarily due to increase in gross profit $170,367 offset by increase in operating expense of $894,892.




7





Liquidity and Capital Resources

As of September 30, 2021, we had cash and equivalents on hand of $62,953 and a negative working capital of $1,099,690. Generally, the primary sources of our funds have been cash from operations, loans from our shareholders and capital contributions. In addition, on May 6, 2021, we filed a registration statement on Form S-1 with the SEC in connection with an offering, on a "best efforts" basis, up to an aggregate of 5,000,000 shares of our Class A common stock at a fixed price of $0.50 per share. We estimate that the net proceeds of this offering will be approximately $2.42 million. We believe that our cash on hand and working capital will be sufficient to meet its anticipated cash requirements through January 31, 2022. We intend to continue working toward identifying and obtaining new sources of financing. No assurances can be given that we will be successful in obtaining additional financing in the future. Any future financing that we may obtain may cause significant dilution to existing stockholders. Any debt financing or other financing of securities senior to common stock that we are able to obtain will likely include financial and other covenants that will restrict our flexibility. Any failure to comply with these covenants would have a negative impact on our business, prospects, financial condition, results of operations and cash flows.

If adequate funds are not available, we may be required to delay, scale back or eliminate portions of our operations, cease operations or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain of our assets. Accordingly, the inability to obtain such financing could result in a significant loss of ownership and/or control of our assets and could also adversely affect our ability to fund our continued operations and our expansion efforts.

During the next 12 months, we expect to incur significant research and development expenses with respect to our products. The majority of our research and development activity is focused on development of our stem cell bank.

We also expect to incur significant legal and accounting costs in connection with being a public company. We expect those fees will be significant and will continue to impact our liquidity. Those fees will be higher as our business volume and activity increases.



Shareholder Loans


On May 11, 2021, we entered into a verbal loan agreement with World Precision Medicine Technology Inc., a company owned and controlled by Cheung Ho Shun, one of our existing shareholders, which provided the Company with a working capital loan in the principal amount of $600,000. As of September 30, 2021, the entire loan amount was outstanding.

As of September 30, 2021, we also had payables due to our shareholder and director, Mr. Yang Wang, in the amount of $326,667, and to Mr. Huang Li, an indirect shareholder, in the amount of $60,585.

All of our shareholder loans are due on demand and non-interest bearing.



Going concern


The accompanying interim unaudited condensed consolidated financial statements for the quarter ended September 30, 2021 included an explanatory paragraph referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a going concern. Our consolidated financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our consolidated financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.




          8

  Table of Contents



Off Balance Sheet Arrangements

We have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder's equity or that are not reflected in its consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

© Edgar Online, source Glimpses

All news about YUBO INTERNATIONAL BIOTECH LIMITED
05/16YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condi..
AQ
05/16Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended..
CI
04/15YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condi..
AQ
04/15Yubo International Biotech Limited Reports Earnings Results for the Full Year Ended Dec..
CI
2021YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condi..
AQ
2021Yubo International Biotech Limited Reports Earnings Results for the Third Quarter and N..
CI
2021YUBO INTERNATIONAL BIOTECH : Management's Discussion and Analysis of Financial Condition a..
AQ
2021Yubo International Biotech Limited Reports Earnings Results for the Second Quarter Ende..
CI
2021YUBO INTERNATIONAL BIOTECH : Management's Discussion and Analysis of Financial Condition a..
AQ
2021Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended..
CI
More news
Financials (USD)
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 8,30 M 8,30 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees 20
Free-Float 5,25%
Chart YUBO INTERNATIONAL BIOTECH LIMITED
Duration : Period :
Yubo International Biotech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Jun Wang President
Lina Liu Chief Financial Officer
Wang Yang General Manager
Zhi Hui Bai Director
Sector and Competitors
1st jan.Capi. (M$)
YUBO INTERNATIONAL BIOTECH LIMITED-83.16%8
INVESTOR AB (PUBL)-17.69%57 656
CK HUTCHISON HOLDINGS LIMITED12.13%27 550
GROUPE BRUXELLES LAMBERT SA-12.90%13 317
HAL TRUST-8.23%12 397
AB INDUSTRIVÄRDEN (PUBL)-10.99%11 227